Literature DB >> 28117100

Multidisciplinary approach in the management of advanced ovarian cancer patients: A personalized approach. Results from a specialized ovarian cancer unit.

Giovanni Damiano Aletti1, Annalisa Garbi2, Pietro Messori2, Maria Teresa Achilarre2, Vanna Zanagnolo2, Stefania Rizzo3, Sarah Alessi3, Luca Bocciolone2, Fabio Landoni2, Roberto Biffi4, Silvestro Carinelli5, Nicoletta Colombo2, Angelo Maggioni2.   

Abstract

OBJECTIVE: The aim of the present study was to evaluate the impact of a multidisciplinary approach in patients' selection with advanced ovarian cancer (AOC) for different therapeutic strategies.
METHODS: Patients referred at our institution between 2009 and 2012 for AOC were included. Primary multidisciplinary evaluation was performed in all patients. Different strategies included: 1. patients referred to primary neoadjuvant chemotherapy (NACT) and interval surgery (IDS) (group A); 2. patients considered for surgical exploration. After surgical exploration, patients were either considered for primary debulking (PDS; group B), or NACT (group C).
RESULTS: A total of 363 patients were included. Of 38 patients (10.5%) in group A, 24 (63%) had sovradiaphragmatic/multiple liver metastases; 14 (37%) were excluded for PDS for anestehesiologic/medical reasons. Of 325 (89.5%) considered for surgical exploration, 295 (91%; group B) had primary surgery with debulking intent (N: 277) and were cytoreduced to no macroscopic disease (R0: N:200; 68%) o minimal RD<5mm (R1: N:77; 26%) or palliative intent (N:18; 6%); 30 (9%; group C) were referred for NACT. Of those, 27 (90%) underwent IDS, 3 had progressive disease. Overall survival (OS) and progression free survival (PFS) was different between the groups: OS: Group A: 34months; Group B: 59months; Group C: 29months; p<0.001. PFS: Group A: 10months; Group B; 21months; Group C: 12months; p<0.001.
CONCLUSIONS: A multidisciplinary approach to patients referred to a tertiary center with AOC allows optimization of the treatment strategy, based on patients' characteristics (age, performance/nutritional status, comorbidities, functional status) and tumor diffusion (evaluated pre- and intraoperatively). Copyright Â
© 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28117100     DOI: 10.1016/j.ygyno.2017.01.017

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  10 in total

1.  Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months.

Authors:  Stefania Rizzo; Francesca Botta; Sara Raimondi; Daniela Origgi; Valentina Buscarino; Anna Colarieti; Federica Tomao; Giovanni Aletti; Vanna Zanagnolo; Maria Del Grande; Nicoletta Colombo; Massimo Bellomi
Journal:  Eur Radiol       Date:  2018-05-08       Impact factor: 5.315

2.  Do DWI and quantitative DCE perfusion MR have a prognostic value in high-grade serous ovarian cancer?

Authors:  Francesca De Piano; Valentina Buscarino; Dulia Maresca; Patrick Maisonneuve; Giovanni Aletti; Roberta Lazzari; Andrea Vavassori; Massimo Bellomi; Stefania Rizzo
Journal:  Radiol Med       Date:  2019-08-31       Impact factor: 3.469

Review 3.  Primary or Interval Debulking Surgery in Advanced Ovarian Cancer: a Personalized Decision-a Literature Review.

Authors:  Delphine Hudry; Stéphanie Bécourt; Giovanni Scambia; Anna Fagotti
Journal:  Curr Oncol Rep       Date:  2022-08-15       Impact factor: 5.945

4.  Comparison of Survival Between Primary Debulking Surgery Versus Neoadjuvant Chemotherapy for Ovarian Cancers in a Personalized Treatment Cohort.

Authors:  Zheng Feng; Hao Wen; Ruimin Li; Shuai Liu; Yi Fu; Xiaojun Chen; Rui Bi; Xingzhu Ju; Xiaohua Wu
Journal:  Front Oncol       Date:  2021-02-10       Impact factor: 6.244

5.  The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies.

Authors:  Meng Qin; Ying Jin; Li Ma; Yan-Yan Zhang; Ling-Ya Pan
Journal:  Oncotarget       Date:  2017-12-27

6.  A triage strategy in advanced ovarian cancer management based on multiple predictive models for R0 resection: a prospective cohort study.

Authors:  Zheng Feng; Hao Wen; Zhaoxia Jiang; Shuai Liu; Xingzhu Ju; Xiaojun Chen; Lingfang Xia; Junyan Xu; Rui Bi; Xiaohua Wu
Journal:  J Gynecol Oncol       Date:  2018-04-23       Impact factor: 4.401

7.  Bowel resection rate but not bowel related morbidity is decreased after interval debulking surgery compared to primary surgery in patents with stage IIIC-IV ovarian cancer.

Authors:  Roberto Tozzi; Jvan Casarin; Ahmet Baysal; Gaetano Valenti; Yakup Kilic; Hooman Soleymani Majd; Matteo Morotti
Journal:  J Gynecol Oncol       Date:  2018-11-30       Impact factor: 4.401

8.  Validation of three predictive models for suboptimal cytoreductive surgery in advanced ovarian cancer.

Authors:  Antoni Llueca; María Teresa Climent; Javier Escrig; Paula Carrasco; Anna Serra
Journal:  Sci Rep       Date:  2021-04-14       Impact factor: 4.379

9.  Do oncologists prefer subspecialty radiology reports? A quality care study.

Authors:  Stefania Rizzo; Maria Del Grande; Vittoria Espeli; Anastasios Stathis; Gabriele Maria Nicolino; Filippo Del Grande
Journal:  Insights Imaging       Date:  2021-05-26

Review 10.  A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review).

Authors:  Luca Falzone; Giuseppa Scandurra; Valentina Lombardo; Giuseppe Gattuso; Alessandro Lavoro; Andrea Benedetto Distefano; Giuseppe Scibilia; Paolo Scollo
Journal:  Int J Oncol       Date:  2021-06-16       Impact factor: 5.650

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.